NEW YORK (GenomeWeb News) – UK phosphoproteomics firm Activiomics today announced it has received a £500,000 ($806,715) investment, which it will use to further build partnerships with pharmaceutical and biotech firms and to identify novel biomarkers.
Leading the round was IP Group. Additional investors included IP Venture Fund and members of Activiomics' management.
The company, based in London, is a spinout of the Institute of Cancer, Barts and the London School of Medicine and Dentistry at Queen Mary, University of London. Its flagship technology called Targeted In-Depth Quantification of Cell Signaling, or TIQUAS, combines phosphoproteomics, mass spectrometry, and a proprietary database and software to investigate cell signaling pathways.
According to the firm, its technology has applications in biomarker and drug discovery in disease areas including oncology and inflammation. In December, Activiomics inked an agreement with biopharma firm UCB for the use of TIQUAS for the analysis and interpretation of cell-signaling pathway activity.